DATE
2024 FDA Drug Approvals: Small Companies Make Significant Impact
FDA drug approvals 2024, small biotech companies, pharmaceutical industry, new drug approvals, regulatory updates.
Abbott and Dexcom Reach 10-Year Settlement Over Diabetes Sensor Patent Disputes
Abbott, Dexcom, diabetes sensor, patent litigation, settlement, 10-year truce, continuous glucose monitoring (CGM)
FDA Approves ALYFTREK, a Next-Generation CFTR Modulator for Cystic Fibrosis Treatment
ALYFTREK, cystic fibrosis, CFTR modulator, FDA approval, once-daily treatment, Vertex Pharmaceuticals
Celebrating Visionaries: Insights from the 2024 Fierce 50 Honorees
Fierce 50, 2024 Honorees, Healthcare Innovation, Biopharma, Health Equity, Patient Advocacy
Biopharmaceutical Manufacturing and Emerging Trends in 2024: A Global Outlook
Biopharmaceutical manufacturing, 2024 trends, personalized medicine, AI-driven drug discovery, biosimilars, cell and gene therapies, biotechnology innovations.
Regeneron’s EYLEA HD Succeeds in Phase 3 Trial for Retinal Vein Occlusion, Paving Way for 2025 FDA Submission
EYLEA HD, Aflibercept, Retinal Vein Occlusion (RVO), Phase 3 QUASAR Trial, Extended Dosing Intervals, FDA Submission 2025, Regeneron Pharmaceuticals
Congress Eyes Major PBM Reforms in Year-End Spending Bill
Pharmacy Benefit Managers (PBMs), PBM reforms, healthcare costs, year-end spending bill, Congress, bipartisan legislation, transparency, drug prices.
ICER Report Highlights $815 Million in Unjustified Drug Price Increases in 2023
ICER report, unsupported drug price hikes, 2023, pharmaceutical costs, healthcare spending
2024 Biotech IPOs: Insights and Trends
Biotech IPOs, 2024 IPO trends, biopharma sector, initial public offerings, venture capital investment, healthcare innovation.
Supreme Court Declines to Review PhRMA’s Challenge to Arkansas’ 340B Contract Pharmacy Law
340B Program, Arkansas Act 1103, PhRMA, Supreme Court, Contract Pharmacies, Drug Pricing, Federal Preemption